Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
HOME > ORGANIZATION
ORGANIZATION
- Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
March 18, 2024
- JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
February 19, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- Payers, HCPs Hail First Step Taken for Generic Industry Revamp in FY2024 Reform
February 15, 2024
- Drug Supply Worsens for 3rd Month Running amid Flu Surge, Shipment Halts
February 13, 2024
- JGA Issues Written Reprimand to Sawai over GMP Issues
January 30, 2024
- JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
January 25, 2024
- Around 70 APIs Right Now Are Good Candidates for Rx-to-OTC Switches: JSMI Chair
January 24, 2024
- Japan Needs National Efforts to Boost Biosimilar Production: Kameda Chief Pharmacist
January 22, 2024
- Ishikawa Pharmacist Group Makes Direct Plea to Health Minister for Ad-Hoc Lifting of Shipment Curbs
January 19, 2024
- JPMA Calls for Setting Broad Spillover Exclusions in Market Expansion Re-Pricing
January 19, 2024
- 80-90% of Clinics in Northern Noto Not Functioning: JMA Official
January 12, 2024
- Wholesalers Ask for Prioritized Drug Supply for Disaster Areas; Emergency Dispensing Scheme Begins
January 11, 2024
- FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- Awareness Rate for Drug Lag, Loss at 17.6%, Up 5.2 Points from FY2022: JPMA Poll
December 22, 2023
- Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
- EFPIA Japan Names Novo’s Mejlvang as New Vice Chair
December 22, 2023
- Pharma Trade Groups Applaud FY2024 Drug Pricing Reform Outline
December 21, 2023
- JMA, JDA, JPA Call for Mitigation Measures for New LLP Coverage Rule
December 21, 2023
ページ
Your reputation as an employer matters.A survey completed by Indeed found that 95% of job seekers found a company’s reputation was an important consideration.When top talent is a scarce commodity, companies need to do more than just make an offer.…
A health ministry panel on pharmaceutical regulations on December 13 discussed the need for confirmatory trial data in Japanese subjects for drugs to treat ultra-rare diseases. The industry proposed waving the implementation of Japanese studies when deemed appropriate in a…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…